Clinical trials: Colorectal Carcinoma (CRC)
Colorectal Cancer
Health Behaviors in Patients Who Have Finished Treatment for Stage I, Stage II, or Stage III Colorectal Cancer
RATIONALE: Gathering information over time from patients who have finished treatment for colorectal cancer may help doctors predict which cancer survivors will improve their physical activity and diet.
- Trial name
- NCT00966667
- Where
- 14 sites in United States
- Volunteers
- 222 people
- Sponsor
- Rutgers, The State University of New Jersey
Colorectal Cancer Metastatic
Precision Medicine for Colorectal Cancer Liver Metastasis Guided by Multi-omics Data Under the Umbrella Theory
In order to more accurately discover the cause of drug resistance in tumor treatment, and to provide a new basis for precise treatment.
- Trial name
- NCT04525807
- Testing
- Multi-omics
- Volunteers
- 200 people
- Sponsor
- Fudan University
Colorectal Cancer
Phase IIa Study of Nimotuzumab to Treat Colorectal Cancer
Nimotuzumab is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR).
- Trial name
- NCT05278728
- Testing
- Nimotuzumab, Irinotecan
- Where
- 2 sites in China
- Volunteers
- 31 people
- Sponsor
- Biotech Pharmaceutical Co., Ltd.
Breast Carcinoma, Cervical Carcinoma
The Ohio State University (OSU) SCREEN Community Program
This clinical trial develops and tests how well a multi-level intervention (MLI), The Ohio State University (OSU) SCREEN Community Program, works to increase screening and follow-up for breast, cervical and colorectal (CRC)…
- Conditions
- Breast Carcinoma, Cervical Carcinoma, Colorectal Carcinoma
- Trial name
- NCT06666192
- Testing
- Cancer Screening, Discussion, Educational Activity
- Where
- United States
- Volunteers
- 2,067 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Colorectal Cancer
IBI310 in Combination with Sintilimab in Patients with DNA Mismatch Repair Deficient (dMMR)/microsatellite Instability High (MSI-H) Locally-advanced or Metastatic Colorectal Cancer
The main purpose of this study is to assess the efficacy and safety of IBI310 in combination with sintilimab in patients with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) locally advance or…
- Trial name
- NCT04258111
- Testing
- IBI310 (anti-CTLA-4 antibody), Sintilimab(anti-PD-1 antibody)
- Where
- China
- Volunteers
- 4 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Breast Cancer, Colo-rectal Cancer
The French E3N Prospective Cohort Study
The French E3N cohort was initiated in 1990 to investigate the risk factors associated with cancer and other major non-communicable diseases in women.
- Conditions
- Breast Cancer, Colo-rectal Cancer, Parkinson Disease, Asthma
- Trial name
- E3N (NCT03285230)
- Where
- France
- Volunteers
- 100,000 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Colo-rectal Cancer
Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy Combined With Penpulimab and Fruquintinib for Advanced Colorectal Cancer
P (Population): Patients with advanced colorectal cancer who have failed at least two prior lines of therapy. I (Intervention): Radiotherapy, immunotherapy, and fruquintinib.
- Trial name
- PRIM-CRC3 (NCT07904130)
- Testing
- Personalized ultrafractionated stereotactic adaptive radiotherapy, Immunotherapy, Target Therapy
- Volunteers
- 32 people
- Sponsor
- West China Hospital
Colorectal Neoplasms, Colorectal Carcinoma
ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer
Background: Irinotecan is a drug that is used to treat colon or rectal cancer. It affects the deoxyribonucleic acid (DNA) of growing cancer cells. It is most often used with other chemotherapy drugs.
- Conditions
- Colorectal Neoplasms, Colorectal Carcinoma, Colorectal Tumors
- Trial name
- NCT01675128
- Testing
- ISIS 183750, Irinotecan
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Adenocarcinoma
Measurement of MMP-14 Protein, a Potential New Marker for Colorectal Cancer Detection, in Plasma Vesicles Named Exosomes
Colorectal cancer is the third most common cancer in men, and the second most common in women. Screening for colorectal cancer is based on the search for blood in the stool using fecal immunochemical test (FIT).
- Trial name
- EXOSCOL02 (NCT06955767)
- Testing
- Blood will be drawn from 2 additional tubes of 5 ml each
- Where
- France
- Volunteers
- 650 people
- Sponsor
- CHU de Reims
Colorectal Cancer
Proactive Outreach With FIT
The purpose of the study is to boost colorectal cancer (CRC) screening rates in an underserved population in Brooklyn through organized, proactive outreach of mailed Fecal Immunochemical Tests (FIT), utilizing evidence-based…
- Trial name
- PROOF (NCT06269744)
- Testing
- Proactive Screening Outreach
- Where
- 2 sites in United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Non-metastatic Colorectal Cancer, Empathy
Role of Empathy in Curative Treatment Outcomes of Non-metastatic Colorectal Cancer.
The aim of project EMPACOL will be to investigate, while taking into consideration the clinical factors known and well described in the literature, among the non-clinical factors, in particular, patient-healthcare personnel (HCP)…
- Conditions
- Non-metastatic Colorectal Cancer, Empathy, Morbidity, Morality
- Trial name
- EMPACOL (NCT05447611)
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- University Hospital, Caen
Colorectal Cancer
Evaluating Personalized Effect of an Individualized Intervention
Energy healing is among the most commonly used forms of complementary and alternative medicine among cancer patients. There are, however, few studies on the effects of energy healing for cancer and cancer associated symptoms and…
- Trial name
- NCT01434264
- Testing
- Energy healing
- Where
- Denmark
- Volunteers
- 247 people
- Sponsor
- University of Southern Denmark
Diseases of Liver, Colon Carcinoma
Lesion Detection Assessment in the Liver: Standard vs Low Radiation Dose Using Varied Post-Processing Techniques
To compare 2 different image creation/processing techniques during a standard CT scan in order to "see" problems in the liver and learn which method provides better image quality.
- Conditions
- Diseases of Liver, Colon Carcinoma, Colorectal Carcinoma, Liver Metastases
- Trial name
- NCT03151564
- Testing
- Computed Tomography Scan - 50% Dose Reduction, Computed Tomography Scan - 70% Dose Reduction, Deep Learning Image Reconstruction (DLIR)
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- M.D. Anderson Cancer Center
Gastrointestinal Carcinoma, Pancreatic Cancer
A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies
Background: Gastrointestinal (GI) cancer affects the organs (such as the stomach, large and small intestine, pancreas, colon, liver, and biliary system) of the digestive tract.
- Conditions
- Gastrointestinal Carcinoma, Pancreatic Cancer, Hepatocellular Cancer, Cholangiocarcinoma
- Trial name
- NCT06690281
- Testing
- KRAS TCR-Transduced PBL, Aldesleukin, Fludarabine
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
Effect of Folate on DNA in Colon Tissue and Blood Samples From Patients at Increased Risk of Developing Colorectal Neoplasia
RATIONALE: Studying samples of blood and tissue from patients at risk of cancer in the laboratory may help doctors learn more about the effect of folate on DNA and identify biomarkers related to cancer.
- Trial name
- NCT00611000
- Testing
- folic acid, DNA methylation analysis, gene expression analysis
- Volunteers
- 20 people
- Sponsor
- Rockefeller University
Lung Cancer, Adult Soft Tissue Sarcoma
Vaccine Therapy in Treating Patients With Metastatic Cancer
RATIONALE: Vaccines made from a peptide may make the body build an immune response and kill tumor cells. PURPOSE: Randomized phase I trial to study the effectiveness of vaccine therapy in treating patients who have metastatic…
- Conditions
- Lung Cancer, Adult Soft Tissue Sarcoma, Colorectal Cancer, Bone Cancer
- Trial name
- NCT00020267
- Testing
- interleukin-2, MAGE-12 peptide vaccine, Montanide ISA-51
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer Control and Prevention, Colorectal Cancer
Prophylactic PIPAC in Patients With High-risk Colorectal Cancer
In a multicentric randomized controlled trial, we will compare standard surgery (consisting in removal of the primary cancer) followed by 6 months of adjuvant chemotherapy associated with 3 cycles of oxaliplatin-based PIPAC (4-6…
- Conditions
- Colorectal Cancer Control and Prevention, Colorectal Cancer, Colorectal Cancer Stage II, Colorectal Cancer Stage III
- Trial name
- PROPAC (NCT06839092)
- Testing
- oxaliplatin-based PIPAC, Control (Standard treatment)
- Volunteers
- 160 people
- Sponsor
- Jeremy Meyer
Colorectal Neoplasm, Colorectal Cancer
New Individualized Therapy Trial for Metastatic Colorectal Cancer
The purpose of this study is to evaluate the safety and tolerability of imatinib mesylate in combination with panitumumab for the treatment of stage IV colorectal cancer that has spread to the liver.
- Trial name
- NITMEC (NCT00867334)
- Testing
- Imatinib mesylate and panitumumab, Standard-of-care treatment with panitumumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Inova Health Care Services
Non Small Cell Lung Cancer, Urothelial Carcinoma
Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors
In this phase I first-in-humans-study a vaccine consisting of arginase-1 (ARG1) peptides and the adjuvant Montanide ISA-51 will be tested in ten patients with metastatic solid tumors.
- Conditions
- Non Small Cell Lung Cancer, Urothelial Carcinoma, Malignant Melanoma, Ovarian Cancer
- Trial name
- NCT03689192
- Testing
- ARG1-18,19,20
- Where
- Denmark
- Volunteers
- 13 people
- Sponsor
- Herlev Hospital
Stage IV Colorectal Cancer, Curative Resection
Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer.
Single-arm, monocentric trial to assess safety and immunological efficacy of adjuvant vaccination with autologous dendritic cells loaded with autologous tumour homogenate after curative resection for stage IV colorectal cancer
- Trial name
- COREVAX-1 (NCT02919644)
- Testing
- autologous dendritic cells loaded with autologous tumour homogenate, IL2
- Where
- 2 sites in Italy
- Volunteers
- 19 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.